###begin article-title 0
Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia
###end article-title 0
###begin p 1
These authors co-directed this work.
###end p 1
###begin p 2
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 972 977 964 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 1003 1009 995 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Srebp1</italic>
###xml 1223 1231 1211 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 444 449 <span type="species:ncbi:10090">mouse</span>
###xml 1087 1095 <span type="species:ncbi:9606">patients</span>
Friedreich's ataxia (FRDA), the most common inherited ataxia, is characterized by focal neurodegeneration, diabetes mellitus and life-threatening cardiomyopathy. Frataxin, which is significantly reduced in patients with this recessive disorder, is a mitochondrial iron-binding protein, but how its deficiency leads to neurodegeneration and metabolic derangements is not known. We performed microarray analysis of heart and skeletal muscle in a mouse model of frataxin deficiency, and found molecular evidence of increased lipogenesis in skeletal muscle, and alteration of fiber-type composition in heart, consistent with insulin resistance and cardiomyopathy, respectively. Since the peroxisome proliferator-activated receptor gamma (PPARgamma) pathway is known to regulate both processes, we hypothesized that dysregulation of this pathway could play a key role in frataxin deficiency. We confirmed this by showing a coordinate dysregulation of the PPARgamma coactivator Pgc1a and transcription factor Srebp1 in cellular and animal models of frataxin deficiency, and in cells from FRDA patients, who have marked insulin resistance. Finally, we show that genetic modulation of the PPARgamma pathway affects frataxin levels in vitro, supporting PPARgamma as a novel therapeutic target in FRDA.
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C1">1</xref>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C2">2</xref>
###xml 707 708 707 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C3">3</xref>
###xml 709 710 709 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C6">6</xref>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
Friedreich's Ataxia (FRDA, OMIM #229300) is an inherited autosomal recessive disorder characterized by progressive neurologic disability, cardiomyopathy and, in some patients, diabetes mellitus (1). FRDA is caused by partial deficiency of the mitochondrial protein frataxin (2). Though the function of frataxin is still partly controversial, there is general agreement that it is involved in cellular iron homeostasis and that its deficiency results in multiple enzyme deficits, mitochondrial dysfunction, and oxidative damage. Complete absence of frataxin is incompatible with life in higher organisms, as demonstrated by the embryonic lethality observed in systemic and conditional gene knock-out models (3-6).
###end p 5
###begin p 6
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C2">2</xref>
###xml 808 809 808 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C7">7</xref>
###xml 810 811 810 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C8">8</xref>
###xml 911 912 911 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C9">9</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C11">11</xref>
###xml 1041 1043 1041 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C12">12</xref>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
###xml 732 740 <span type="species:ncbi:9606">patients</span>
###xml 858 866 <span type="species:ncbi:9606">patients</span>
Residual frataxin amounts vary between 5 and 35% of normal levels in FRDA patients, and are little more than 50% in heterozygous carriers, who show no sign of disease (2). A clear pattern of selective vulnerability to this partial loss of frataxin can be observed in FRDA. In the nervous system, neurodegeneration affects the large primary sensory neurons in the dorsal root ganglia and their axons in peripheral nerves and in the dorsal columns of the spinal cord, the spinocerebellar pathways, the dentate nucleus in the cerebellum, the distal part of the corticospinal tract and, to a variable extent, the auditory and visual pathways. Cardiac involvement is present in most patients at the preclinical level, and 45-63% of FRDA patients have hypertrophic cardiomyopathy, which can cause premature death (7,8). Overt diabetes is present in 14-19% of FRDA patients, and glucose intolerance is seen in 24-40% (9-11). Skeletal muscle is only sub-clinically involved in FRDA, as a reduced ATP production can be detected with MR spectroscopy (12), but the causal metabolic pathways have not been identified.
###end p 6
###begin p 7
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C13">13</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C14">14</xref>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 522 527 <span type="species:ncbi:9606">human</span>
Reducing frataxin expression in mice to levels similar to those observed in FRDA (KIKO mice) induced a biochemical CNS phenotype (13) but not clinical abnormalities (14). To study the selective vulnerability to frataxin deficiency in a model where no confounding non-specific or secondary degenerative changes are expected to occur, we have utilized frataxin-deficient mice to investigate gene expression profiles in the heart, a major target of FRDA pathology, and in skeletal muscle, only sub-clinically affected in the human disease. This unbiased genome-wide analysis, which we further extended to liver and cellular models, confirmed the hypothesis that frataxin deficiency causes tissue-specific changes in several metabolic pathways. Involvement of the peroxisome-proliferator activator receptor gamma (PPARgamma)/PPARgamma coactivator 1 alpha (Pgc1a) pathway in several cell types may serve as key regulator of FRDA pathogenesis, including enhanced risk of diabetes and cardiomyopathy.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Functional genomic analysis of frataxin deficient mice
###end title 9
###begin p 10
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F1">1</xref>
###xml 620 621 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 644 645 644 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 659 660 659 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F1">1</xref>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C13">13</xref>
###xml 910 912 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C15">15</xref>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 162 167 <span type="species:ncbi:10090">Mouse</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
We analyzed tissue from heart and skeletal muscle from four KIKO mice compared with control littermates. We used two array platforms (Agilent G4121A and Illumina Mouse RefSeq Expression arrays, see Materials and Methods), in order to increase our detection power. Unsupervised array clustering clearly separates the two tissues (Fig. 1A), confirming distinct expression profiles. Because cardiac involvement is most clinically evident, we expected more changes in the cardiac tissue than skeletal muscle. However, in KIKO mice versus WT littermates, we found more differentially expressed (DE) genes in skeletal muscle (n = 321) than in heart (n = 174) (Fig. 1B and C), suggesting a level of complexity in the tissue-specific response to frataxin deficiency that we had not anticipated. We observed a preponderance of downregulated genes in both tissues. This confirms previous reports in this (13) and other (15) FRDA models, and suggests that frataxin deficiency induces a prevalent downregulation of gene expression. Furthermore, we observed distinct expression patterns in each muscle type, consistent with distinct downstream effects of frataxin deficiency in these distinct tissues.
###end p 10
###begin p 11
###xml 64 65 64 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 350 351 350 351 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 605 606 605 606 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1055 1056 1055 1056 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1061 1062 1061 1062 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1365 1366 1365 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1412 1442 1412 1442 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="http://david.abcc.ncifcrf.gov/">http://david.abcc.ncifcrf.gov/</uri>
###xml 1638 1639 1638 1639 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1844 1848 1844 1848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Myh4</italic>
###xml 1878 1882 1878 1882 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Scd2</italic>
###xml 1884 1890 1884 1890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Slc2a5</italic>
###xml 1892 1896 1892 1896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acly</italic>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
###xml 1178 1182 <span type="species:ncbi:10090">mice</span>
Microarray analysis of heart and skeletal muscle in KIKO mice. (A) Array clustering based on mean average deviation shows sample clustering by tissue. Within tissues, samples tend to cluster by genotype. Color coding bars: Top (genotype): red, WT samples; black, KIKO samples. Left side (tissue): red, skeletal muscle samples; black, heart samples. (B) Number of differentially expressed genes at P < 0.005. Three-hundred and twenty-one probes (194 downregulated, 127 upregulated) were differentially expressed in skeletal muscle; 174 (106 downregulated, 68 upregulated) in heart of KIKO mice versus WT; (C) Heatmap depicting fold changes in cardiac and skeletal muscle samples in KIKO mice versus controls. Shades of red represent upregulation, shades of green downregulation. Genes and samples are clustered by similarity. Most genes have tissue-specific changes, whereas a subset of genes present changes across tissues. Color coding bar: yellow, skeletal muscle samples (KIKO versus average of WT); orange: heart samples (KIKO versus average of WT); (D and E) Gene ontology analysis of differentially expressed genes in heart and skeletal muscle samples from KIKO versus WT mice. Top categories include 'sterol' and 'lipid metabolic process' in skeletal muscle and 'regulation of muscle contraction' in heart. Bars represent the -Log of the over-representation P-value, as calculated by the DAVID algorithm (http://david.abcc.ncifcrf.gov/). Red and green represent the proportion of up and downregulated genes, respectively. The number at the end of the bar represents the number of probes differentially expressed in each category; (F) Real-time quantitative PCR (qPCR) confirmation on 14 among the top differentially expressed genes. Fold changes are expressed in log2. Error bars: standard error. qPCR confirmed tissue specificity (e.g. Myh4 only downregulated in heart, Scd2, Slc2a5, Acly only upregulated in skeletal muscle).
###end p 11
###begin p 12
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F1">1</xref>
###xml 447 453 447 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Srebp1</italic>
###xml 465 470 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acas2</italic>
###xml 472 476 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Scd2</italic>
###xml 481 485 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aacs</italic>
###xml 566 571 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Socs3</italic>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C16">16</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C17">17</xref>
###xml 725 729 725 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mod1</italic>
###xml 808 810 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C18">18</xref>
###xml 915 919 915 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tnn1</italic>
###xml 921 925 921 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Myl3</italic>
###xml 927 932 927 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tnnc1</italic>
Three-hundred and twenty-one probes (corresponding to 308 unique gene names) were DE between KIKO and WT skeletal muscle. The most DE genes are reported in , and the complete gene list is reported in . The top Gene Ontology (GO) categories (; Fig. 1D) include lipid metabolism (overall upregulated), transcriptional regulation and signal transduction. Ingenuity Pathway analysis () showed that a number of targets of the transcriptional regulator Srebp1 (including Acas2, Scd2 and Aacs) were also upregulated in skeletal muscle. We also observed increased levels of Socs3, which has been linked to insulin resistance (16) and diabetes (17). Interestingly, we found a significant upregulation of the cytosolic malic enzyme 1 (Mod1), confirming a previous report of increased activity in FRDA muscle biopsies (18). Some contractile proteins were also dysregulated (mostly downregulated) in skeletal muscle, including Tnn1, Myl3, Tnnc1. We observed an over-representation of downregulated contractile proteins expressed in slow-twitch fibers, which would lead to a prevalence of fast, more anaerobic, less-oxidative fiber type, in contrast to the signature observed in cardiac muscle (see in what follows).
###end p 12
###begin p 13
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F1">1</xref>
###xml 376 380 376 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mapk</italic>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C13">13</xref>
###xml 645 649 645 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Myh4</italic>
###xml 651 656 651 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tnnc2</italic>
###xml 661 666 661 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tnni2</italic>
###xml 757 763 757 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Atp2a1</italic>
###xml 765 770 765 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tnnc2</italic>
###xml 772 777 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tnni2</italic>
###xml 779 784 779 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tnnt3</italic>
###xml 835 841 835 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Atp2a1</italic>
###xml 910 916 910 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Serca1</italic>
###xml 1081 1083 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C19">19</xref>
###xml 1160 1162 1160 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C20">20</xref>
One-hundred and seventy-four probes (corresponding to 169 unique gene names) showed differential expression in heart ( and S4). The top GO categories (; Fig. 1E) include 'regulation of muscle contraction' (overall downregulated), 'oxidoreductase activity' and 'regulation of cell cycle'. Ingenuity Pathway analysis () showed an overrepresentation of mitogen-activated kinase (Mapk) targets, confirming the involvement of this pathway as an early biochemical change in response to frataxin deficiency (13). Most strikingly, in heart a number of core proteins of the muscle-fiber contractile apparatus showed significant downregulation, including Myh4, Tnnc2 and Tnni2 (). Downregulated genes were mostly associated with aerobic, fast-twitch myofibrils (e.g. Atp2a1, Tnnc2, Tnni2, Tnnt3)-an opposite trend compared with skeletal muscle. Atp2a1 (also known as sarcoplasmic/endoplasmic reticulum calcium ATPase 1, Serca1) is involved in calcium sequestration and muscular excitation/contraction. Downregulation of SERCAs has been associated with cardiomyopathy in a number of studies (19), and its upregulation is beneficial for cardiac function in animal models (20). Only 6% of DE genes in heart were also dysregulated in skeletal muscle, indicating a differential effect of frataxin deficiency on these two metabolically distinct muscle tissues.
###end p 13
###begin p 14
###xml 193 194 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F1">1</xref>
We selected 14 genes to represent a cross-section of DE genes expressed at different levels and in different tissues, for validation by qPCR. We confirmed approximately71% of the targets (Fig. 1F)-a high confirmation rate, considered the magnitude of the observed changes and the sensitivity of qPCR.
###end p 14
###begin p 15
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C21">21</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C22">22</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C23">23</xref>
###xml 653 658 653 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C24">24</xref>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C25">25</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C27">27</xref>
###xml 1131 1136 1131 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 1143 1147 1143 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mmp9</italic>
###xml 1149 1151 1149 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C28">28</xref>
###xml 1154 1159 1154 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fabp3</italic>
###xml 1161 1163 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C29">29</xref>
###xml 1166 1171 1166 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Socs3</italic>
###xml 1173 1175 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C30">30</xref>
Taken together, these data suggest an upregulation of lipidogenic enzymes in skeletal muscle, and a shift in fiber-type composition in both heart and skeletal muscle, in opposing directions. In heart, these expression changes, together with changes in calcium-related genes (21), are compatible with early signs of cardiomyopathy, whereas in skeletal muscle (a major insulin target) these data suggest a derangement of fuel metabolism related to early changes occurring in insulin resistance and type 2 diabetes (T2D). Pgc1a and the sterol-responsive element binding protein 1 (Srebp1) are master regulators of lipid biosynthesis and breakdown (22,23). Pgc1a is also known to control the muscle fiber-type ratio (24), and both factors are involved in insulin resistance and diabetes (25-27). Since the dysregulation of these two master transcriptional regulators provides a parsimonious explanation for the tissue-specific transcriptional changes that we observed, we hypothesized that they are directly affected by frataxin deficiency. Further supporting this hypothesis, we found that other genes whose expression is affected by Pgc1a [e.g. Mmp9 (28), Fabp3 (29), Socs3 (30)] are also dysregulated.
###end p 15
###begin p 16
We generated cellular models of frataxin deficiency using short hairpin RNA interference (shRNAi) and followed the effects of transient frataxin downregulation on a set of target genes identified in the microarray study. In such models, expression changes occurring over a short time period (12-72 h) can be more confidently attributed to a direct, primary effect of frataxin deficiency, rather than a secondary degenerative process due to long-term cellular changes.
###end p 16
###begin p 17
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</sup>
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</italic>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F2">2</xref>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Isu</italic>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C31">31</xref>
###xml 357 361 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mthf</italic>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C15">15</xref>
###xml 560 565 560 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 586 592 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Srebp1</italic>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F2">2</xref>
###xml 708 714 708 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Elovl3</italic>
###xml 716 721 716 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acas2</italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acly</italic>
###xml 777 780 777 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</sup>
###xml 883 884 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F2">2</xref>
###xml 923 929 923 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparbp</italic>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C13">13</xref>
###xml 974 978 <span type="species:ncbi:10090">mice</span>
###xml 1005 1013 <span type="species:ncbi:9606">patients</span>
Transfection of C2C12 myoblasts with an anti-frataxin shRNA (shRNAiFxn) induced an average 50% downregulation of the Fxn transcript and protein that started at 12 h, peaked at 24-32 and lasted up to 72 h (Fig. 2A and B). In these cells, we observed dysregulation of a set of genes already known to be downstream of frataxin deficiency, such as Isu (31) and Mthf (15), thus validating them as a cellular model of frataxin deficiency. Consistent with our interpretation of the microarray findings in KIKO skeletal muscle, we found a coordinate downregulation of Pgc1a and upregulation of Srebp1 (Fig. 2A,C,D). Accordingly, two out of three tested lipogenic genes that were upregulated in KIKO skeletal muscle (Elovl3, Acas2, Acly) also showed a significant upregulation in shRNAiFxn-transfected C2C12 cells, peaking at 48 h after transfection (24 h after frataxin downregulation, Fig. 2A). In addition, PPAR-binding protein (Pparbp), which was downregulated in brains of KIKO mice and fibroblasts from FRDA patients (13), was also downregulated.
###end p 17
###begin p 18
###xml 7 8 7 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 20 21 20 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 452 453 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 473 474 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 482 483 482 483 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 633 636 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</sup>
###xml 647 648 647 648 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 656 659 656 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</sup>
###xml 758 759 758 759 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 882 883 882 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</sub>
###xml 888 890 888 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 894 896 894 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 983 984 982 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1007 1008 1006 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1045 1046 1044 1045 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1067 1068 1066 1067 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</sub>
###xml 1167 1168 1166 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1178 1179 1177 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1190 1191 1189 1190 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 1337 1338 1336 1337 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</sub>
###xml 1460 1461 1459 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1524 1525 1523 1524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1581 1582 1580 1581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 766 774 <span type="species:ncbi:9606">patients</span>
###xml 936 944 <span type="species:ncbi:9606">patients</span>
###xml 1056 1064 <span type="species:ncbi:9606">patients</span>
###xml 1300 1308 <span type="species:ncbi:9606">patients</span>
###xml 1554 1562 <span type="species:ncbi:9606">patients</span>
C2C12 (A) and HL-1 (B) cells were transfected with shRNAi for frataxin. Expression levels of frataxin versus cells transfected with control shRNAi were assessed at 12, 24, 32, 48 and 72 h after transfection (top panel). Expression levels of nine genes were assessed at 24 and 48 h after transfection (bottom panel). Red bars: upregulated genes; green bars: downregulated genes. Fold changes are expressed in log2. Error bars: standard error. Asterisk: P < 0.05, one-sample t-test. (C) Representative western blots (top) and blot quantification (bottom) for Frataxin and Srebp1 after transfection with control shRNAi (left) and shRNAiFxn (right). (D) shRNAiFxn transfection reduces Pgc1a expression as measured by a luciferase assay in 293 cells after 24 h. (E) FRDA patients have a significantly lower insulin sensitivity index: boxplots representing the insulin sensitivity index SI [x10-5 min-1/(muU/ml)] in healthy controls and FRDA patients, matched for age and body mass index. n = 14 in each group, **P < 0.005 by Wilcoxon rank sum test. (F) In FRDA patients, SI was significantly inversely correlated with the number of GAA repeats on the smaller FRDA allele (r = -0.55, P < 0.05). (G) Physical impairment scores are not significantly different between insulin-resistant and insulin-sensitive patients; the bar graph depicts the SI (left) and the physical impairment scores [on a scale from 0 (normal) to 42 (most severe impairment), right] of the 50% (n = 7) most insulin sensitive (light gray bars) and of the 50% (n = 7) most insulin resistant patients (dark gray bars); P = 0.5 for comparison between the two groups.
###end p 18
###begin p 19
###xml 136 139 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</sup>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparbp</italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F2">2</xref>
To check the specificity for skeletal muscle-derived cells of the above changes, as suggested the by microarray data, we generated shRNAFxn-transfected HL-1 cardiomyocytes. Though these cells showed a 40-50% frataxin mRNA downregulation, no significant changes in lipogenic genes occurred, whereas Pparbp and Pgc1a showed a non-significant trend towards upregulation (Fig. 2B), in concordance with the KIKO heart expression profiling findings.
###end p 19
###begin p 20
###xml 617 621 617 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acac</italic>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acas2</italic>
###xml 849 854 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 859 865 859 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Srebp1</italic>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
We next tested the hypothesis that the changes observed in skeletal muscle represent systemic metabolic changes consistent with fuel shift and potential insulin resistance. Because liver is a major player in fuel metabolism and insulin response, we analyzed global patterns of gene expression in the liver of 3 KIKO mice compared to 3 WT mice using microarrays. This analysis identified 182 DE probes in KIKO versus WT mice ( and ). Strikingly, by GO analysis, lipid metabolism was among the top categories showing a significant enrichment in liver (B). Many dysregulated genes were shared with skeletal muscle (e.g. Acac, Acas2). In addition, other lipid-related genes showed liver-specific changes (), consistent with a systemic metabolic rearrangement towards increased lipogenesis in frataxin deficiency. These observations further suggest that Pgc1a and Srebp1 are likely to play a central role in this transcriptional response. To summarize this concept, a potential model that is parsimonious with these data is depicted in .
###end p 20
###begin title 21
###xml 5 13 <span type="species:ncbi:9606">patients</span>
FRDA patients are insulin resistant
###end title 21
###begin p 22
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C9">9</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C32">32</xref>
###xml 443 444 443 444 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</sub>
###xml 486 488 482 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 492 494 488 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 561 562 556 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 583 584 578 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 599 600 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F2">2</xref>
###xml 741 742 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 752 753 747 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 767 768 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F2">2</xref>
###xml 1235 1236 1230 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1287 1288 1282 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1337 1338 1332 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F2">2</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
###xml 457 465 <span type="species:ncbi:9606">patients</span>
###xml 779 787 <span type="species:ncbi:9606">patients</span>
###xml 1225 1233 <span type="species:ncbi:9606">patients</span>
###xml 1277 1285 <span type="species:ncbi:9606">patients</span>
The finding that gene expression profiles in KIKO mice skeletal muscle and liver were suggestive of decreased insulin sensitivity prompted us to test insulin sensitivity in 14 non-diabetic FRDA patients by intravenous glucose-tolerance testing and minimal model analysis of glucose kinetics. Confirming previous reports (9,32), we found that non-diabetic FRDA patients were insulin resistant compared with controls [insulin sensitivity index SI 20 +/- 2 in patients versus 34 +/- 3 x 10-5 min-1/(muU/ml) in healthy controls matched for age and body mass index, n = 14 in each group, P < 0.005, Fig. 2E and G]. Furthermore, insulin sensitivity was significantly inversely correlated with the number of GAA repeats in the smaller FRDA allele (r = -0.55, P < 0.05, Fig. 2F) in FRDA patients, indicating that it is directly linked to the degree of frataxin deficiency. To exclude that the severity of neurological impairment, possibly because of the resulting reduced motor activity, rather than the degree of frataxin depletion was the cause of insulin resistance, we compared the score on a neurological impairment rating scale ranging from 0 (normal) to 42 (most severe impairment) between the 50% more insulin sensitive FRDA patients (n = 7) and the 50% more insulin resistant patients (n = 7), and found no significant difference (Fig. 2G), suggesting that frataxin deficiency directly causes insulin resistance, independent of physical impairment.
###end p 22
###begin title 23
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
The PPARgamma pathway is dysregulated in frataxin deficient mice and FRDA patients
###end title 23
###begin p 24
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 261 264 261 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</italic>
###xml 264 272 264 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(GAA)230</italic>
###xml 264 272 264 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>(GAA)230</italic></sup>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C33">33</xref>
###xml 335 338 335 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</italic>
###xml 343 348 343 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 501 502 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F3">3</xref>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
We assessed whether Pgc1a is dysregulated in additional cell types, including CNS cells, strengthening the causal connection between frataxin and Pgc1a downregulation. We cultured neural precursor cells (NPCs) from the subventricular zone (SVZ) from homozygous Fxn(GAA)230 (KIKI) mice (33), KIKO mice and WT littermates and quantified Fxn and Pgc1a transcript levels using RT-qPCR. Pgc1a transcript levels were decreased by approximately25% in KIKI- and by approximately70% in KIKO-derived NPCs (Fig. 3A).
###end p 24
###begin p 25
###xml 86 94 82 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 97 98 93 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 103 104 99 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 106 111 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 238 239 234 235 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 265 267 261 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xn</italic>
###xml 285 290 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 386 387 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 400 401 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 417 418 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 486 487 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 514 515 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 611 616 583 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 714 717 686 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</italic>
###xml 821 822 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 856 857 828 829 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 868 873 840 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 919 922 891 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</italic>
###xml 936 937 908 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 937 938 909 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 946 947 918 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1022 1023 994 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1064 1065 1036 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1073 1074 1045 1046 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1079 1080 1051 1052 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1082 1087 1054 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGC1A</italic>
###xml 1230 1231 1202 1203 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1253 1254 1225 1226 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1332 1337 1304 1309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</sup>
###xml 1456 1457 1428 1429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1482 1483 1454 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1595 1596 1567 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 186 191 <span type="species:ncbi:10090">mouse</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 1038 1046 <span type="species:ncbi:9606">patients</span>
###xml 1398 1406 <span type="species:ncbi:9606">patients</span>
Genetic and pharmacologic modulation of the PPARgamma pathway affects frataxin levels in vitro. (A and B) Pgc1a levels are correlated with frataxin levels in neural precursor cells from mouse models and in cells from patients with FRDA. (A) qPCR quantification of Fxn (white bars) and Pgc1a (blue bars) in neural precursor cells from the subventricular zone (SVZ-NPC) in wild-type (WT, n = 3), KIKI (n = 3) and KIKO (n = 3) mice, and in lymphoblasts and fibroblasts from FRDA patients (n = 4) and normal controls (n = 3). KIKI mice express approximately75% of normal frataxin levels, and KIKO approximately30%. Pgc1a mRNA expression levels are reduced in all these cell lines, in a degree which is proportional to Fxn downregulation. Bars represent the average of six replicates, error bars represent the standard error. P < 0.05 for all the comparisons; (B) Relative Pgc1a levels are strongly correlated with relative Fxn mRNA levels (r2 = 0.9, P < 0.001); qPCR quantification in fibroblasts from controls (open circles, n = 3) and FRDA patients (filled circles, n = 4). (C and D) PGC1A downregulation via siRNAi reduces frataxin protein levels in control fibroblasts, and further in FRDA fibroblasts. Western blotting analysis (C) and quantification (D) of PGC-1A (top) and FXN (bottom) protein 72 h after transfection with siRNAiPgc1a. Control and FRDA are fibroblasts from healthy controls and patients, respectively. All experiments were performed on n = 4 FRDA cell lines and n = 3 control cell lines. Bars represent the average of six replicates, error bars represent the standard error. P < 0.05 for all comparisons.
###end p 25
###begin p 26
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGC1A</italic>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F3">3</xref>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGC1A</italic>
###xml 345 348 345 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FXN</italic>
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 386 387 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 395 396 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F3">3</xref>
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
To extend these observations to human patients, we studied lymphoblastoid cell lines and primary skin fibroblasts from FRDA patients. In both cell types we observed a 70-80% downregulation of PGC1A relative to normal controls (Fig. 3A). Furthermore, when we examined results from FRDA fibroblasts, a strong correlation emerged between PGC1A and FXN expression, normalized to controls (r2 = 0.9, P < 0.001, Fig. 3B).
###end p 26
###begin title 27
PPARgamma manipulation affects frataxin levels
###end title 27
###begin p 28
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C34">34</xref>
###xml 540 545 540 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGC1A</italic>
###xml 540 545 540 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>PGC1A</italic></sup>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F3">3</xref>
###xml 1073 1075 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C35">35</xref>
###xml 1128 1130 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C36">36</xref>
###xml 390 395 <span type="species:ncbi:9606">human</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
Pgc1a plays a key role in mitochondrial biogenesis and function by promoting the expression of several genes involved in mitochondrial DNA replication and in oxidative phosphorylation (34). The importance of frataxin for normal mitochondrial function makes it a possible target of PGC1A, prompting us to test whether PGC1A manipulation can affect frataxin levels. We downregulated PGC1A in human fibroblasts using a specific siRNA and observed a significant decrease in frataxin mRNA and protein levels after a 72-h transfection with siRNAiPGC1A in both FRDA patients and controls (Fig. 3C and D). Thus, a positive feedback loop between PGC1A and frataxin levels appears to exist. We hypothesize that, when frataxin is primarily abnormally low, as in FRDA, the resulting impairment of this feedback loop is likely to further aggravate frataxin deficiency. Conversely, a pharmacological intervention to activate PGC1A should help re-establishing the positive feedback and therefore increase frataxin levels. The recent report that the potent PPARgamma agonist Azelaoyl-PAF (35) is able to increase frataxin levels in FRDA cells (36) supports this model.
###end p 28
###begin title 29
DISCUSSION
###end title 29
###begin p 30
###xml 665 670 <span type="species:ncbi:10090">mouse</span>
###xml 770 778 <span type="species:ncbi:9606">patients</span>
###xml 1053 1058 <span type="species:ncbi:9606">human</span>
Neurodegenerative diseases affect specific subsets of neurons and in some cases non-nervous system structures as well, but the reasons underlying such selective cellular vulnerability are largely unknown. Reduced frataxin levels in FRDA are likely to have some downstream consequences that are the same in all cell types, along with consequences and adaptive responses that are cell and tissue-specific. We took an unbiased, genome-wide approach to obtain clues on FRDA pathogenesis and selective vulnerability. We analyzed how global gene expression profiles are affected in the heart (affected in FRDA), skeletal muscle and liver (not clinically affected) from a mouse model expressing frataxin at levels (about 30-35% of normal) corresponding to mildly affected FRDA patients, and yet not showing obvious clinical or pathological abnormalities. We observed the same basic pattern of dysregulation in skeletal muscle and liver, consistent with their roles in energy metabolism. However heart muscle, which is significantly affected by myopathy in the human disease, showed changes suggesting a fiber-type switch and dysregulation of contractile proteins, possibly consistent with cardiomyopathy.
###end p 30
###begin p 31
###xml 483 485 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C23">23</xref>
###xml 549 554 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 725 730 721 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acas2</italic>
###xml 732 736 728 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Scd2</italic>
###xml 738 742 734 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acly</italic>
###xml 744 748 740 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aacs</italic>
###xml 750 756 746 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Elovl3</italic>
###xml 852 858 848 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Srebp1</italic>
###xml 1098 1100 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C37">37</xref>
###xml 1217 1219 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C38">38</xref>
###xml 1220 1222 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C39">39</xref>
###xml 1338 1340 1334 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C40">40</xref>
###xml 1341 1343 1337 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C41">41</xref>
###xml 1459 1464 1455 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 1589 1590 1585 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C9">9</xref>
###xml 1714 1716 1710 1712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C42">42</xref>
###xml 1717 1719 1713 1715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C43">43</xref>
###xml 1794 1796 1790 1792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C44">44</xref>
###xml 1933 1935 1929 1931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C45">45</xref>
###xml 1936 1938 1932 1934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C46">46</xref>
###xml 1994 1995 1990 1991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C6">6</xref>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 1385 1393 <span type="species:ncbi:9606">patients</span>
###xml 1535 1543 <span type="species:ncbi:9606">patients</span>
###xml 1704 1712 <span type="species:ncbi:9606">patients</span>
###xml 2082 2090 <span type="species:ncbi:9606">patients</span>
###xml 2338 2346 <span type="species:ncbi:9606">patients</span>
Dysregulation of the PPARgamma/PGC1A pathway was observed in tissues from animal and cellular models of frataxin deficiency, as well as in cells from FRDA patients, suggesting that this is a general downstream effector of frataxin deficiency. Pgc1a is the most studied of the peroxisome proliferator activated receptor co-activators (PGCs), a family of transcriptional co-activators that regulate mitochondrial biogenesis, energy substrate and utilization, and oxidative metabolism (23). In KIKO skeletal muscle and liver, our results indicate that Pgc1a activity is downregulated, as shown by the increased expression in both tissues of a set of genes involved in lipogenesis that are normally repressed by Pgc1a, including Acas2, Scd2, Acly, Aacs, Elovl3. These changes are also supported by the simultaneous upregulation of the transcription factor Srebp1. In skeletal muscle, changes in expression of contractile proteins that would result in increased glycolytic fast-twitch fibers and decreased slow, oxidative fibers type I and IIa, provide further evidence of downregulated Pgc1a activity (37). Pgc1a downregulation, and the related Srebp1 upregulation, are known to occur in insulin resistance and diabetes (38,39), along with reduced mitochondrial oxidative phosphorylation and lower oxidative-to-glycolytic muscle fiber ratio (40,41). The increased risk of diabetes in FRDA patients is therefore likely to be a consequence of the downregulation of Pgc1a in key tissues for insulin response and fuel metabolism control. FRDA patients are insulin resistant before being diabetic (9), and higher incidence of glucose intolerance and insulin resistance has been reported in family members of FRDA patients (42,43). However, other reports suggest a primary beta-cell involvement in FRDA (44), and a pathogenic mechanism primarily involving beta-cell failure has been proposed based on studies in other mitochondrial disorders (45,46) and on the pancreatic conditional frataxin knock-out (6). Here, we confirm that insulin resistance is present in all tested non-diabetic FRDA patients, strongly supporting the hypothesis suggested by our gene expression data that insulin target tissues are relevant in the pathogenesis of diabetes in FRDA. Furthermore, we show here for the first time that the degree of insulin resistance of FRDA patients correlates with GAA repeat size (hence to lower residual frataxin levels) and is independent of neurological impairment, in agreement with the hypothesis that it is a direct consequence of frataxin deficiency.
###end p 31
###begin p 32
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C47">47</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C40">40</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C48">48</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C26">26</xref>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C18">18</xref>
###xml 1201 1202 1201 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP183F4">4</xref>
###xml 560 568 <span type="species:ncbi:9606">patients</span>
###xml 782 786 <span type="species:ncbi:10090">mice</span>
Though the direct mechanistic link between frataxin and PGC1A remains to be completely defined, it is very likely related to mitochondrial dysfunction caused by frataxin deficiency. Mitochondrial dysfunction also occurs in T2D (47), as shown by 30% reduction of ATP production in skeletal muscle, associated with increased intramyocellular lipid (IML) content and decreased aerobic/anaerobic muscle fiber ratio (40,48). IML content, a consequence of increased lipid synthesis, is strongly correlated with glucose intolerance and insulin resistance in diabetic patients and can trigger insulin resistance (26). No data are available on IMLs in FRDA muscle, but the finding of increased cytosolic malic enzyme activity (18), in perfect concordance with gene expression data from KIKO mice, at least suggests increased lipogenesis and a metabolic shift similar to T2D. We propose therefore that in FRDA, like in T2D, a state of insulin resistance and associated metabolic changes long precedes the onset of clinically overt diabetes, which is eventually due to pancreatic beta-cell failure. Beta-cell failure may in turn be accelerated by intrinsic mitochondrial dysfunction due to the gene defect (Fig. 4).
###end p 32
###begin p 33
###xml 190 196 190 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc-1a</italic>
###xml 201 208 201 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Srebp-1</italic>
Diabetes in FRDA and type-2 diabetes may have a final common pathway. In normal conditions (left panel), lipid breakdown and biosynthesis are tightly controlled by the two master regulators Pgc-1a and Srebp-1. In type-2 diabetes (center), increased dietary lipids provided to the skeletal muscle can overload TCA and divert long-chain-CoA species into lipid precursors than can be converted in lipids, leading to an increased lipid intramyocellular content, which in turn leads to reduced glucose transport, reduced glycogen synthesis and ultimately to insulin resistance. In FRDA (right), deficits of TCA enzymes occur, as well as decreased activity of complexes I-II-III of the respiratory chain. An ineffective TCA and mitochondrial OXPHOS would lead to TCA overflow, favoring a metabolic shift toward the redirection of citrate from the TCA cycle and electron transport chain to processing into fatty acids. In mitochondrial diseases and in FRDA in particular, the oxidative stress can contribute to the diabetes pathogenesis at both (i) skeletal muscle and liver (insulin targets) and (ii) the beta-cell level, leading to overt diabetes mellitus. TCA, tricarboxylic acid cycle; IMLs, intra-myocellular lipids.
###end p 33
###begin p 34
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 238 241 238 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fxn</sup>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C49">49</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C50">50</xref>
###xml 702 707 702 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C51">51</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C52">52</xref>
###xml 837 842 837 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pgc1a</italic>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C53">53</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C54">54</xref>
###xml 1065 1067 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C51">51</xref>
###xml 1202 1204 1202 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C23">23</xref>
###xml 1205 1207 1205 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C55">55</xref>
###xml 532 537 <span type="species:ncbi:10090">mouse</span>
###xml 721 736 <span type="species:ncbi:10090">transgenic mice</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
In contrast with skeletal muscle, we observed a downregulation of fast fibers in cardiac muscle, which also suggests an increased Pgc1a effect. We also observed a trend towards Pgc1a upregulation in HL-1 cardiomyocytes treated with shRNAiFxn. Though apparently contradictory, these data actually confirm Pgc1a as a primary target of frataxin deficiency while underlining tissue-specific differences in this response. Our findings are indeed consistent with the observation that Pgc1a mRNA levels are elevated in the myocardium in a mouse model of metabolic syndrome (49) and with data suggesting a role for increased Pgc1a levels in diabetic cardiomyopathy (50). Furthermore, chronic overexpression of Pgc1a in hearts of transgenic mice induces cardiomyopathy (51,52), while only mild cardiac abnormalities are observed in the hearts of Pgc1a knock-out mice (53,54). The idea that Pgc1a can have opposite changes in different tissues is supported by the fact that its overexpression induces uncoupled respiration in adipose tissue and coupling in cardiac myocytes (51). Pgc1a binding to tissue-specific transcription factors, enabling the activation of diverse metabolic programs in different tissues (23,55), offers an explanation for these differences and the distinct metabolic effects observed in skeletal and cardiac muscle in this model of frataxin deficiency ().
###end p 34
###begin p 35
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C56">56</xref>
###xml 177 179 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C36">36</xref>
This model was supported by recent reports that (i) PGC1A overexpression in skeletal muscle cells (56) and (ii) treatment of FRDA cells with the PPARgamma agonist Azelaoyl-PAF (36) are able to increase frataxin levels. PPARgamma agonists such as rosiglitazone and pioglitazone are in clinical use as oral antidiabetics. The latter molecule may be of particular interest because of its capacity to cross the blood-brain barrier. Clearly, the opposite dysregulation of Pgc1a in the heart imposes caution for any attempt to clinically test such a drug in FRDA. Maybe not surprisingly, cardiac toxicity is a known side effect of this class of drugs.
###end p 35
###begin p 36
###xml 830 838 <span type="species:ncbi:9606">patients</span>
In conclusion, we have identified distinct pattern of gene expression changes in metabolically distinct tissues in a model of frataxin deficiency. These data suggest Pgc1a as a key regulator of gene expression that is directly affected by frataxin deficiency and in turn affects frataxin expression. Further studies (such as frataxin overexpression) are needed to characterize the relationship between Fxn and Pgc1a. Downregulation of Pgc1a is the rule in several frataxin-deficient cell types, including skeletal muscle, liver, lymphoblasts, fibroblasts and possibly the pathologically relevant CNS cells, engaging a feedback loop that leads to even lower frataxin levels, reduced antioxidant defenses and mitochondrial function. Such a mechanism appears to be responsible in particular for the vulnerability to diabetes of FRDA patients. In these cell types, upregulation of Pgc1a using PPARgamma agonists may be an appealing therapeutic approach.
###end p 36
###begin title 37
MATERIALS AND METHODS
###end title 37
###begin title 38
Animals and tissue samples
###end title 38
###begin p 39
###xml 31 39 31 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">230GAA/-</sup>
###xml 72 85 72 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">230GAA/230GAA</sup>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C14">14</xref>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
Frataxin knockout/knockin (Frda230GAA/-, KIKO) and knockin/knockin (Frda230GAA/230GAA, KIKI) mice were obtained as described (14). Four 6-month-old male KIKO and three 6-month-old male KIKI mice were compared with age and gender-matched WT littermates. Total RNA from skeletal muscle (gastrocnemius), heart and liver was extracted by acid phenol extraction (Trizol, GIBCO/BRL) as recommended by the manufacturer.
###end p 39
###begin title 40
Microarrays
###end title 40
###begin p 41
Sample preparation and array hybridization and scanning were performed according to established protocols (detailed in ). Quality control, differential expression, and cross-platform microarray analysis were performed using Bioconductor packages in the R statistical environment (see  for a detailed description). The microarray data have been deposited in the NCBI Gene Expression Omnibus database (GEO, www.ncbi.nlm.nih.gov/geo) with the GEO series accession number GSE15849.
###end p 41
###begin title 42
Cell culture
###end title 42
###begin p 43
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
###xml 504 511 <span type="species:ncbi:9606">patient</span>
###xml 542 547 <span type="species:ncbi:9606">Human</span>
###xml 656 661 <span type="species:ncbi:10090">Mouse</span>
###xml 745 749 <span type="species:ncbi:10090">mice</span>
###xml 858 863 <span type="species:ncbi:9606">human</span>
###xml 893 898 <span type="species:ncbi:9606">human</span>
C2C12 cells were obtained from ATCC (Manassas, VA) and HL-1 cells were a kind gift from the Claycomb Lab (School of Medicine, LSU, New Orleans, LA). Fibroblasts primary cell cultures were obtained from skin biopsies of FRDA patients and healthy controls after receiving written informed consent. All the patients were homozygous for the GAA repeat expansion (500-1700 repeats), and were being treated with Idebenone 5 mg/kg. Epstein Barr virus-transformed lymphoblast cell lines GM15850 were from a FRDA patient (650-1030 GAA repeats; NIGMS, Human Genetic Cell Repository at the Coriell Institute, Camden, NJ, USA) and GM15851 from one unaffected control. Mouse neuronal precursor cells (NPC-SVZ) were obtained from wild-type and from KIKI/KIKO mice. Brain layer of tissue surrounding the ventricles was cultured in the media containing 20 ng/ml recombinant human EGF and 10 ng/ml recombinant human bFGF (Peprotech, NJ, USA). Derived neurospheres were plated in a fresh growth medium and were assessed for their characteristics of self-renewal and multipotentiality. Cells were transfected using standard procedures, detailed in .
###end p 43
###begin title 44
qPCR experiments
###end title 44
###begin p 45
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C13">13</xref>
Real-time quantitative PCR experiments were performed as described previously (13) and in .
###end p 45
###begin title 46
Western blot and luciferase assays
###end title 46
###begin p 47
Western blot and luciferase assays were performed using standard procedures, detailed in .
###end p 47
###begin title 48
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Assessment of physical impairment in FRDA patients
###end title 48
###begin p 49
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C57">57</xref>
Speech, upright stability, upper limb coordination, and lower limb coordination scores from the FARS (57) scale were used.
###end p 49
###begin title 50
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Assessment of insulin sensitivity in FRDA patients and healthy controls
###end title 50
###begin p 51
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C58">58</xref>
###xml 793 794 793 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</sub>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP183C59">59</xref>
###xml 5 13 <span type="species:ncbi:9606">patients</span>
FRDA patients and healthy volunteers provided written informed consent. After an overnight fast, subjects underwent an intravenous glucose-tolerance test to measure insulin sensitivity. Glucose (0.3 g/kg) was infused intravenously, followed by an insulin infusion (0.025 U/kg) 20 min later, and blood was sampled at times -15, -5 and -1 min before intravenous glucose administration, and at 2, 3, 4, 5, 6, 8, 10, 14, 16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160 and 180 min (58). Plasma glucose was measured using the glucose oxidase method (DiaSys, Holzheim, Germany). Plasma insulin concentrations were measured by ELISA (INSI-CTK immunoradiometric analysis; DiaSorin, Saluggia, Italy). Insulin sensitivity was quantified as the insulin sensitivity index (SI) based on the glucose and insulin data using the minimal model of glucose kinetics (59).
###end p 51
###begin title 52
SUPPLEMENTARY MATERIAL
###end title 52
###begin p 53
.
###end p 53
###begin title 54
[Supplementary Data]
###end title 54
###begin title 55
FUNDING
###end title 55
###begin p 56
###xml 49 86 49 86 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Friedreich&#8217;s Ataxia Research Alliance</grant-sponsor>
###xml 87 105 87 105 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDA Seek-A-Miracle</grant-sponsor>
###xml 128 219 128 219 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">the Dr Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF, to D.H.G. and G.C.)</grant-sponsor>
###xml 221 252 221 252 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">the Waverly Smith Memorial fund</grant-sponsor>
###xml 271 311 271 311 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">the National Ataxia Foundation (to M.C.)</grant-sponsor>
###xml 653 682 653 682 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Institutes of Health</grant-sponsor>
###xml 765 821 765 821 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="http://www.fa-petition.org/en/attivita/progetti2008.html">http://www.fa-petition.org/en/attivita/progetti2008.html</uri>
This work was supported by a research grant from Friedreich's Ataxia Research Alliance/MDA Seek-A-Miracle (to G.C. and D.H.G.); the Dr Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF, to D.H.G. and G.C.); the Waverly Smith Memorial fund gift (to D.H.G.); the National Ataxia Foundation (to M.C.); the Fonds National de la Recherche Scientifique (FNRS) - Fonds de la Recherche Scientifique Medicale (FRSM) (to M.C.); grants from Fondazione Gofar (Italy), Fondazione CRT (Italy), French Friedreich Ataxia Association (AFAF), FNRS, and Belgian Ministry for Scientific Policy (Interuniversity Attraction Poles Program 6) to M.P.; and by the National Institutes of Health [grant number NS34192 to M.P.]. D.M. received a fellowship from GOFAR foundation (http://www.fa-petition.org/en/attivita/progetti2008.html). Funding to pay the Open Access charge was provided by AMRF.
###end p 56
###begin title 57
ACKNOWLEDGEMENTS
###end title 57
###begin p 58
###xml 247 254 <span type="species:ncbi:9606">patient</span>
The authors thank Andrew Chen, Marie-Anne Neef and Maren Engelhardt for technical assistance; Eric Wexler, Raj Ratan and Peter Tontonoz for helpful discussions; Audrey Begu, Chantal Depondt and Francoise Fery for help with the Friedreich's ataxia patient studies; Satyan Chintawar for help with neural precursor cells; Coriell Cell Repositories for providing FRDA and control fibroblast and lymphoblast cell lines; and the Claycomb lab for providing the HL-1 cell line.
###end p 58
###begin p 59
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement</italic>
Conflict of Interest statement. None declared.
###end p 59
###begin title 60
REFERENCES
###end title 60
###begin article-title 61
Friedreich ataxia
###end article-title 61
###begin article-title 62
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion
###end article-title 62
###begin article-title 63
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits
###end article-title 63
###begin article-title 64
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia
###end article-title 64
###begin article-title 65
###xml 131 135 <span type="species:ncbi:10090">mice</span>
Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice
###end article-title 65
###begin article-title 66
Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass
###end article-title 66
###begin article-title 67
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Clinical and genetic abnormalities in patients with Friedreich's ataxia
###end article-title 67
###begin article-title 68
Accuracy of clinical diagnostic criteria for Friedreich's ataxia
###end article-title 68
###begin article-title 69
Glucose metabolism alterations in Friedreich's ataxia
###end article-title 69
###begin article-title 70
Glucose and insulin metabolism in Friedreich's ataxia
###end article-title 70
###begin article-title 71
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Genetic data and natural history of Friedreich's disease: a study of 80 Italian patients
###end article-title 71
###begin article-title 72
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia
###end article-title 72
###begin article-title 73
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Gene expression profiling in frataxin deficient mice: microarray evidence for significant expression changes without detectable neurodegeneration
###end article-title 73
###begin article-title 74
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
Frataxin knockin mouse
###end article-title 74
###begin article-title 75
Friedreich ataxia: the oxidative stress paradox
###end article-title 75
###begin article-title 76
###xml 135 140 <span type="species:ncbi:10090">mouse</span>
Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse
###end article-title 76
###begin article-title 77
###xml 117 125 <span type="species:ncbi:9606">patients</span>
Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients
###end article-title 77
###begin article-title 78
Skeletal muscle NAD+(P) and NADP+-dependent malic enzyme in Friedreich's ataxia
###end article-title 78
###begin article-title 79
The Ca2+ ATPase of cardiac sarcoplasmic reticulum: Physiological role and relevance to diseases
###end article-title 79
###begin article-title 80
Expression of SERCA isoform with faster Ca2+ transport properties improves postischemic cardiac function and Ca2+ handling and decreases myocardial infarction
###end article-title 80
###begin article-title 81
###xml 90 94 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats
###end article-title 81
###begin article-title 82
Regulation of sterol synthesis in eukaryotes
###end article-title 82
###begin article-title 83
PGC-1 coactivators: inducible regulators of energy metabolism in health and disease
###end article-title 83
###begin article-title 84
Transcriptional co-activator PGC-1[alpha] drives the formation of slow-twitch muscle fibres
###end article-title 84
###begin article-title 85
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
###end article-title 85
###begin article-title 86
Etiology of insulin resistance
###end article-title 86
###begin article-title 87
Disordered lipid metabolism and the pathogenesis of insulin resistance
###end article-title 87
###begin article-title 88
Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid
###end article-title 88
###begin article-title 89
###xml 148 152 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats
###end article-title 89
###begin article-title 90
Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression
###end article-title 90
###begin article-title 91
Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones
###end article-title 91
###begin article-title 92
Glucose intolerance in Friedreich's ataxia: association with insulin resistance and decreased insulin binding
###end article-title 92
###begin article-title 93
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model
###end article-title 93
###begin article-title 94
PGC-1{alpha}: a key regulator of energy metabolism
###end article-title 94
###begin article-title 95
Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists
###end article-title 95
###begin article-title 96
PPAR-gamma agonist azelaoyl PAF increases frataxin protein and mRNA expression. New implications for the Friedreich's ataxia therapy
###end article-title 96
###begin article-title 97
Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism
###end article-title 97
###begin article-title 98
###xml 100 105 <span type="species:ncbi:9606">human</span>
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
###end article-title 98
###begin article-title 99
###xml 58 64 <span type="species:ncbi:9606">humans</span>
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1
###end article-title 99
###begin article-title 100
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes
###end article-title 100
###begin article-title 101
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM
###end article-title 101
###begin article-title 102
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Glucose intolerance in first-degree relatives of patients with Friedreich's ataxia is associated with insulin resistance: evidence for a closely linked inherited trait
###end article-title 102
###begin article-title 103
Friedreich's ataxia and oral glucose tolerance: I. The effect of ingested glucose on serum glucose and insulin values in homozygotes, obligate heterozygotes and potential carriers of the Friedreich's ataxia gene
###end article-title 103
###begin article-title 104
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Preclinical and manifest diabetes mellitus in young patients with Friedreich's ataxia: no evidence of immune process behind the islet cell destruction
###end article-title 104
###begin article-title 105
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Impaired insulin secretion and beta-cell loss in tissue-specific knockout mice with mitochondrial diabetes
###end article-title 105
###begin article-title 106
Neurodegenerative disorders associated with diabetes mellitus
###end article-title 106
###begin article-title 107
Mitochondrial dysfunction and type 2 diabetes
###end article-title 107
###begin article-title 108
###xml 31 36 <span type="species:ncbi:9606">human</span>
Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes
###end article-title 108
###begin article-title 109
Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway
###end article-title 109
###begin article-title 110
The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus
###end article-title 110
###begin article-title 111
Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis
###end article-title 111
###begin article-title 112
Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner
###end article-title 112
###begin article-title 113
PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis
###end article-title 113
###begin article-title 114
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice
###end article-title 114
###begin article-title 115
Metabolic control through the PGC-1 family of transcription coactivators
###end article-title 115
###begin article-title 116
PGC-1{alpha} is coupled to HIF-1{alpha}-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells
###end article-title 116
###begin article-title 117
Measuring Friedreich ataxia: complementary features of examination and performance measures
###end article-title 117
###begin article-title 118
Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes
###end article-title 118
###begin article-title 119
###xml 89 94 <span type="species:ncbi:9606">human</span>
Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function
###end article-title 119

